Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the primary focus of Australia's mRNA facility after COVID-19 by end of 2025?
Influenza • 25%
Cancer • 25%
HIV • 25%
Other • 25%
Official announcements or production focus reports from the facility
Australia Opens First mRNA Vaccine Facility, Government Maintains Vaccine Use Amid Safety Concerns
Dec 4, 2024, 07:43 AM
The Australian government has announced that it will not suspend the use of mRNA COVID-19 vaccines, despite concerns raised by some scientists regarding potential health risks, including an increased risk of cancer. This decision coincides with the opening of Australia's first mRNA vaccine manufacturing facility, which has the capacity to produce up to 100 million vaccine doses annually. The facility is intended to bolster the country's ability to protect its population from illnesses and diseases. Vaccine skepticism persists among segments of the population, as debates about the safety and efficacy of mRNA technology continue.
View original story
Pandemic Preparedness • 25%
Vaccine Distribution • 25%
Disease Surveillance • 25%
Public Health Education • 25%
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
Pandemic-related products • 25%
Oncology • 25%
Vaccines • 25%
Other • 25%
Cancer immunotherapy • 25%
Influenza vaccine • 25%
HIV vaccine • 25%
Other • 25%
No contamination detected • 25%
Low levels of plasmid DNA detected • 25%
Moderate levels of plasmid DNA detected • 25%
High levels of plasmid DNA detected • 25%
Patient Care Improvement • 25%
Biomedical Research • 25%
Pandemic Preparedness • 25%
Other • 25%
Vaccine procurement • 25%
Public transparency • 25%
Border control measures • 25%
Other • 25%
Influenza • 25%
Zika Virus • 25%
HIV • 25%
Other • 25%
Influenza • 25%
Zika • 25%
HIV • 25%
Other • 25%
Canberra • 25%
Sydney • 25%
Melbourne • 25%
Other • 25%
Treatment of A. baumannii infections • 25%
Treatment of other bacterial infections • 25%
Pandemic preparedness • 25%
Other • 25%
Significant issues found • 25%
Undetermined • 25%
No issues found • 25%
Minor issues found • 25%